Taho Pharmaceuticals (ROCO:6467) Net Margin %: -22,583.52% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
35 GF Score
Price NT$113.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals Net Margin %?

Taho Pharmaceuticals ROCO:6467 -4.22% 35 Net Margin % is -22,583.52% as of Dec. 2025. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Taho Pharmaceuticals ranks worse than 97.81% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Taho Pharmaceuticals's Net Income for the six months ended in Dec. 2025 was NT$-142.50 Mil. Taho Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was NT$0.63 Mil. Therefore, Taho Pharmaceuticals's net margin for the quarter that ended in Dec. 2025 was -22,583.52%.

The historical rank and industry rank for Taho Pharmaceuticals's Net Margin % or its related term are showing as below:

ROCO:6467' s Net Margin % Range Over the Past 10 Years
Min: -11321.11   Med: -620.07   Max: -211.88
Current: -2549.32

ROCO:6467's Net Margin % is ranked worse than
97.81% of 961 companies
in the Drug Manufacturers industry
Industry Median: 5.58 vs ROCO:6467: -2549.32

Taho Pharmaceuticals  (ROCO:6467) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Taho Pharmaceuticals Net Margin % Related Terms

Taho Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals Net Margin % Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only -303.19 -1,105.89 -11,321.11 0.00 -2,549.32

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,450.11 0.00 0.00 -924.23 -22,583.52

ROCO:6467 vs ZTS, UTHR: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taho Pharmaceuticals Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Taho Pharmaceuticals's Net Margin % falls into.


ROCO:6467
35GF Score
Taho Pharmaceuticals Ltd ROCO:6467
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Taho Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-214.398/8.41
=-2,549.32 %

Taho Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-142.502/0.631
=-22,583.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -22,583.52% mean?
Taho Pharmaceuticals (ROCO:6467) has a Net Margin % of -22,583.52% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Taho Pharmaceuticals and its competitors. According to the industry distribution chart, Taho Pharmaceuticals ranks #940 out of 961 companies in the Drug Manufacturers industry, placing it in the top 97.8%.
Is Taho Pharmaceuticals' Net Margin % too high?
Taho Pharmaceuticals' current Net Margin % is -22,583.52%. Based on the distribution chart, Taho Pharmaceuticals ranks #940 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taho Pharmaceuticals ranks #940 out of 961 companies for Net Margin %. This places Taho Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Taho Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current Net Margin % is -22,583.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Net Margin % of -22,583.52%. The current Net Margin % is -22,583.52%. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Net Margin % is -22,583.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score

Get the complete analysis for ROCO:6467

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$113.50
Price